pI: 10.5199 |
Length (AA): 609 |
MW (Da): 72686 |
Paralog Number:
1
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 1
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
NA% percentile | ME49 Oocyst. | Fritz HM |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 0-20% percentile | VEG Tachyzoite, ME49 Tachyzoite, ME49 merozoite, ME49 Bradyzoite. | Gregory Hehl AB Sibley/Greg |
Sibley/Greg | ToxoDB |
Fritz HM | Transcriptomic analysis of toxoplasma development reveals many novel functions and structures specific to sporozoites and oocysts. |
Hehl AB | Asexual expansion of Toxoplasma gondii merozoites is distinct from tachyzoites and entails expression of non-overlapping gene families to attach, invade, and replicate within feline enterocytes. |
Gregory | ToxoDB |
Ortholog group members (OG5_136933)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | ArthCp012 | RNA polymerase beta'' chain |
Babesia bovis | BBOV_V000110 | rpoC2-N-terminal |
Babesia bovis | BBOV_V000100 | hypothetical protein |
Plasmodium berghei | PBANKA_API00170 | RNA polymerase D |
Plasmodium falciparum | PF3D7_API04200 | RNA polymerase D |
Plasmodium knowlesi | PKNH_API05100 | RNA polymerase sigma factor RpoD, putative |
Plasmodium yoelii | PY04440 | hypothetical protein |
Toxoplasma gondii | TGME49_300690 | RNA polymerase C2, putative |
Toxoplasma gondii | TGME49_355200 | hypothetical protein |
Theileria parva | TP05_0042 | DNA-directed RNA polymerase beta'' chain, putative |
Theileria parva | TP05_0043 | DNA-directed RNA polymerase beta'' chain, putative |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.